Stocks · News reference
Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors
Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — CRESCENT BIOPHARMA, INC. (CBIO)
Filed: 2026-10-15 AccNo: 0001628280-26-066006 Size: 157 KB Item 8.01: Other Events
Crescent Biopharma Says Initial Data From Phase 1/2 CR-001 Trial On Track For Q1 2027; Sees Potential Phase 3 Start In Early 2028
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.